Answers are grounded in this paper and cite their sources.
Osteoarthritis (OA) is a chronic whole-joint degenerative disease. Synovial mesenchymal stem cells (SMSCs) and their derived exosomes (SMSC-Exos) have attracted increasing attention because of their close interaction with the joint microenvironment and their paracrine regenerative potential. However, whether donor aging compromises the cartilage-reparative capacity of SMSC-Exos and the key molecular mechanisms underlying this effect remain unclear. Human SMSCs from young and aged donors were isolated and cultured by enzymatic digestion and plastic-adherence selection, and SMSC-Exos were obtained by ultracentrifugation. Exosomes were characterized by transmission electron microscopy, nanoparticle tracking analysis (NTA), exosomal marker detection, and uptake assays. Using an IL-1β-induced human chondrocyte injury model and a destabilization of the medial meniscus (DMM)-induced male mouse OA model, we systematically evaluated the effects of young- and aged-donor SMSC-Exos and intra-articularly delivered synovial cell-targeted AAV-miR-10a-5p on chondrocyte proliferation, migration, apoptosis, oxidative stress, mitochondrial function, matrix metabolism, and OA progression. Exosomal miRNA sequencing, qRT-PCR, dual-luciferase reporter assays, CRTAC1 overexpression rescue experiments, and mitophagy assays were integrated to explore the mechanism of the miR-10a-5p/CRTAC1 axis. Aged donor-derived SMSCs exhibited senescence-associated alterations, including increased cell size, a higher proportion of SA-β-gal-positive cells, and elevated P16, P21, and P53 expression, but retained MSC surface markers and multilineage differentiation capacity. SMSC-Exos from both young and aged donors displayed typical vesicular morphology and were internalized by chondrocytes; however, Young-Exos were superior to Aged-Exos in promoting chondrocyte proliferation and migration, reducing IL-1β-induced apoptosis and ROS accumulation, and restoring mitochondrial membrane potential and mitochondrial network integrity. In vivo, Young-Exos more effectively improved gait abnormalities, pain-related behavior, osteophyte formation, cartilage proteoglycan loss, and COL2A1/MMP-13 imbalance in OA mice than Aged-Exos. miRNA sequencing identified miR-10a-5p as a Young-Exos-enriched candidate associated with autophagy, mitochondrial function, and inflammatory pathways. Mechanistically, miR-10a-5p suppressed CRTAC1 by binding to the human CRTAC1 3′UTR reporter and reduced CRTAC1 expression in chondrocytes. miR-10a-5p increased Parkin and LC3B expression, decreased p62 accumulation, promoted mitochondria-lysosome colocalization, restored COL II and ACAN expression, and inhibited MMP13, whereas CRTAC1 overexpression partially reversed these protective effects. Synovium-targeted intra-articular delivery of AAV-miR-10a-5p reduced CRTAC1 and NLRP3 levels, restored LC3B-associated mitophagy signaling, decreased p62 accumulation, and attenuated DMM-induced cartilage degeneration and synovitis. Donor aging weakens the cartilage-repair potential of SMSC-Exos by reshaping their miRNA cargo. miR-10a-5p enriched in Young-Exos targets CRTAC1, thereby relieving CRTAC1-associated mitochondrial dysfunction and impaired mitophagy, restoring chondrocyte matrix homeostasis, and delaying OA progression. These findings provide a new rationale for donor selection and miRNA engineering in SMSC-Exos–based cell-free therapy for OA.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: